HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Acute myeloid leukemia following therapy of Hodgkin's disease with radiotherapy and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine).

Abstract
A 26-year-old man developed myelodysplasia rapidly progressing to acute myelomonocytic leukemia 3 years after receiving three cycles of ABVD chemotherapy and upper mantle and upper abdomen radiotherapy for stage IA Hodgkin's disease. This represents the fourth such case reported. The risk of secondary AML after ABVD or radiation therapy is discussed.
AuthorsJ H Lipton, M Gospodarowicz, S Reingold
JournalHematological oncology (Hematol Oncol) Vol. 14 Issue 1 Pg. 29-31 (Mar 1996) ISSN: 0278-0232 [Print] England
PMID8613133 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Bleomycin
  • Vincristine
  • Vinblastine
  • Dacarbazine
  • Doxorubicin
Topics
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Bleomycin (adverse effects, therapeutic use)
  • Combined Modality Therapy
  • Dacarbazine (adverse effects, therapeutic use)
  • Doxorubicin (adverse effects, therapeutic use)
  • Hodgkin Disease (drug therapy, radiotherapy)
  • Humans
  • Leukemia, Myeloid, Acute (chemically induced, etiology)
  • Leukemia, Radiation-Induced (etiology)
  • Male
  • Vinblastine
  • Vincristine (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: